These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25964530)

  • 41. An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate.
    Williams LJ; Mukherjee D; Fisher M; Reyes-Aldasoro CC; Akerman S; Kanthou C; Tozer GM
    Br J Pharmacol; 2014 Nov; 171(21):4902-13. PubMed ID: 24930520
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Power Doppler ultrasound and contrast-enhanced ultrasound demonstrate non-invasive tumour vascular response to anti-vascular therapy in canine cancer patients.
    Abma E; Stock E; De Spiegelaere W; Van Brantegem L; Vanderperren K; Ni Y; Vynck M; Daminet S; De Clercq K; de Rooster H
    Sci Rep; 2019 Jun; 9(1):9262. PubMed ID: 31239493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radiation-guided targeting of combretastatin encapsulated immunoliposomes to mammary tumors.
    Pattillo CB; Venegas B; Donelson FJ; Del Valle L; Knight LC; Chong PL; Kiani MF
    Pharm Res; 2009 May; 26(5):1093-100. PubMed ID: 19172383
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
    Dark GG; Hill SA; Prise VE; Tozer GM; Pettit GR; Chaplin DJ
    Cancer Res; 1997 May; 57(10):1829-34. PubMed ID: 9157969
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of combretastatin A-4 phosphate on canine normal and tumor tissue-derived endothelial cells.
    Izumi Y; Aoshima K; Hoshino Y; Takagi S
    Res Vet Sci; 2017 Jun; 112():222-228. PubMed ID: 28527400
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of natural porcine surfactant in Staphylococcus aureus induced pro-inflammatory cytokines and reactive oxygen species generation in monocytes and neutrophils from human blood.
    de Guevara YL; Hidalgo OB; Santos SS; Brunialti MK; Faure R; Salomao R
    Int Immunopharmacol; 2014 Aug; 21(2):369-74. PubMed ID: 24874441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Colon tumor growth and antivascular treatment in mice: complementary assessment with MR elastography and diffusion-weighted MR imaging.
    Jugé L; Doan BT; Seguin J; Albuquerque M; Larrat B; Mignet N; Chabot GG; Scherman D; Paradis V; Vilgrain V; Van Beers BE; Sinkus R
    Radiology; 2012 Aug; 264(2):436-44. PubMed ID: 22692038
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The vascular-disrupting agent, combretastatin-A4-phosphate, enhances neurogenic vasoconstriction in rat small arteries.
    Su J; Laursen BE; Eskildsen-Helmond Y; Horsman MR; Simonsen U
    Eur J Pharmacol; 2012 Nov; 695(1-3):104-11. PubMed ID: 22981665
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.
    Holwell SE; Cooper PA; Grosios K; Lippert JW; Pettit GR; Shnyder SD; Bibby MC
    Anticancer Res; 2002; 22(2A):707-11. PubMed ID: 12017147
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study.
    Gaya A; Daley F; Taylor NJ; Tozer G; Qureshi U; Padhani A; Pedley RB; Begent R; Wellsted D; Stirling JJ; Rustin G
    Br J Cancer; 2008 Jul; 99(2):321-6. PubMed ID: 18612312
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preclinical Evaluation of Radioiodinated Hoechst 33258 for Early Prediction of Tumor Response to Treatment of Vascular-Disrupting Agents.
    Zhang D; Gao M; Yao N; Jiang C; Liu W; Li T; Song S; Huang D; Yin Z; Qiu Y; Jin Q
    Contrast Media Mol Imaging; 2018; 2018():5237950. PubMed ID: 29681781
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
    Breidahl T; Nielsen FU; Stødkilde-Jørgensen H; Maxwell RJ; Horsman MR
    Acta Oncol; 2006; 45(3):306-16. PubMed ID: 16644574
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice.
    Maria de Souza C; Fonseca de Carvalho L; da Silva Vieira T; Cândida Araújo E Silva A; Teresa Paz Lopes M; Alves Neves Diniz Ferreira M; Passos Andrade S; Dantas Cassali G
    Biomed Pharmacother; 2012 Oct; 66(7):491-8. PubMed ID: 22705333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors.
    Mitrus I; Sochanik A; Cichoń T; Szala S
    Acta Biochim Pol; 2009; 56(1):161-5. PubMed ID: 19287800
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Monitoring the treatment efficacy of the vascular disrupting agent CA4P.
    Salmon BA; Salmon HW; Siemann DW
    Eur J Cancer; 2007 Jul; 43(10):1622-9. PubMed ID: 17451938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy.
    Satterlee AB; Rojas JD; Dayton PA; Huang L
    Theranostics; 2017; 7(2):253-269. PubMed ID: 28042332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combretastatin A4-phosphate and its potential in veterinary oncology: a review.
    Abma E; Daminet S; Smets P; Ni Y; de Rooster H
    Vet Comp Oncol; 2017 Mar; 15(1):184-193. PubMed ID: 25988493
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability.
    Beauregard DA; Hill SA; Chaplin DJ; Brindle KM
    Cancer Res; 2001 Sep; 61(18):6811-5. PubMed ID: 11559555
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats.
    Ke Q; Bodyak N; Rigor DL; Hurst NW; Chaplin DJ; Kang PM
    Vascul Pharmacol; 2009; 51(5-6):337-43. PubMed ID: 19737629
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.
    Tozer GM; Prise VE; Wilson J; Locke RJ; Vojnovic B; Stratford MR; Dennis MF; Chaplin DJ
    Cancer Res; 1999 Apr; 59(7):1626-34. PubMed ID: 10197639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.